Peripheral Sensory Neurons In Chemotherapy Induced Neuropathy is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of many commonly used chemotherapeutic agents, affecting an estimated 30-40% of patients undergoing cancer treatment. CIPN manifests as symmetric, distal sensorypredominant neuropathy that can persist long after chemotherapy cessation, significantly impacting quality of life and functional outcomes.
Taxanes (paclitaxel, docetaxel):
- Disrupt microtubule dynamics essential for axonal transport
- Cause accumulation of microtubule fragments in neuronal cytoplasm
- Lead to distal axonal degeneration through impaired organelle trafficking
- Activate mitochondrial dysfunction and oxidative stress pathways
Vinca Alkaloids (vincristine, vinblastine):
- Inhibit microtubule polymerization in axons
- Disrupt axonal transport machinery
- Particularly affect large myelinated fibers
- Can cause severe sensory-motor neuropathy
Platinum Compounds (oxaliplatin, cisplatin, carboplatin):
- Form DNA cross-links in dorsal root ganglion neurons
- Cause accumulation of platinum-DNA adducts
- Trigger neuronal apoptosis through p53-dependent pathways
- Oxaliplatin associated with acute cold-induced dysesthesia
Bortezomib:
- Impairs ubiquitin-proteasome system in peripheral neurons
- Causes accumulation of misfolded proteins
- Activates endoplasmic reticulum stress response
- Predominantly affects small fiber neurons
Thalidomide and analogs:
- Inhibit angiogenesis and tumor necrosis factor-alpha
- Cause sensory neuropathy through unknown mechanisms
- Dose-dependent toxicity with prolonged treatment
CIPN is strongly associated with mitochondrial dysfunction in peripheral neurons:
- Decreased mitochondrial membrane potential
- Increased reactive oxygen species (ROS) production
- Impaired ATP generation
- Mitochondrial DNA damage
- Opening of mitochondrial permeability transition pores
- Altered calcium signaling in dorsal root ganglion neurons
- Dysregulation of voltage-gated calcium channels
- Impaired mitochondrial calcium buffering
- Activation of calcium-dependent proteases (calpains)
- Disruption of fast axonal transport
- Impaired delivery of structural proteins and organelles
- Accumulation of cytoskeletal proteins
- Distal-to-proximal "dying back" axonopathy
¶ Inflammation and Immune Activation
- Satellite glial cell activation in DRG
- Release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Macrophage infiltration into peripheral nerves
- Activation of toll-like receptor pathways
- Positive symptoms: Burning pain, electric shock-like sensations, paresthesia, allodynia
- Negative symptoms: Numbness, reduced sensation to pinprick, vibration, proprioception
- Distribution: Symmetric, starting in toes/feet, progressing proximally ("stocking-glove" pattern)
- Temperature sensitivity: Particularly prominent with oxaliplatin (cold-induced)
- Mild distal weakness in severe cases
- Reduced deep tendon reflexes
- Gait instability when proprioception affected
- Orthostatic hypotension
- Gastrointestinal dysmotility
- Urinary retention
- Abnormal sweating
- Responsible for vibration sense and proprioception
- Affected particularly by taxanes and vincristine
- Loss leads to sensory ataxia and gait instability
- Transmit pain and temperature
- Vulnerable to bortezomib and platinum agents
- Small fiber neuropathy may present with pain alone
- Postganglionic sympathetic and parasympathetic fibers
- Mediate cardiovascular, gastrointestinal, and sudomotor function
- Affected in severe CIPN
CIPN shares several mechanistic features with classic neurodegenerative diseases:
| Agent |
Evidence |
Notes |
| Duloxetine |
Level 1 evidence |
First FDA-approved for CIPN; SNRI |
| Gabapentin/Pregabalin |
Mixed evidence |
May provide modest benefit |
| Tricyclic antidepressants |
Limited evidence |
Amitriptyline, nortriptyline |
| Lamotrigine |
Negative trials |
Not recommended |
| Topical agents |
Limited evidence |
Capsaicin, lidocaine patches |
- Neurotrophic factors: BDNF, GDNF delivery
- Antioxidants: Acetyl-L-carnitine, coenzyme Q10
- Mitochondrial protectants: Pioglitazone, oltipraz
- Calcium channel modulators: L-type and T-type inhibitors
- Sodium channel blockers: Mexiletine
- CRMP2 targeting: Colchicine derivatives
- Dose scheduling: Lower doses with more frequent administration
- Cryotherapy: Cold gloves/socks during infusion (oxaliplatin)
- Pharmacological prevention: Glutamine, glutathione, calcium/magnesium
- Paclitaxel-induced: Multiple low-dose injections replicate sensory-predominant neuropathy
- Cisplatin-induced: Chronic administration causes DRG pathology
- Vincristine-induced: Rapid onset, severe sensory neuropathy
- Oxaliplatin-induced: Acute cold hypersensitivity followed by chronic neuropathy
- Species differences in drug metabolism
- Difficulty replicating chronic persistent neuropathy
- Often fail to capture pain component adequately
- Total and phosphorylated neurofilament light chain (NfL)
- pNfH in serum/CSF
- Intraepidermal nerve fiber density (skin biopsy)
- Quantitative sensory testing (QST)
- Genetic polymorphisms predicting CIPN risk
- Proteomic signatures in plasma/CSF
- Mitochondrial function assays
- Inflammatory markers (IL-6, TNF-α)
- CRMP2 modifiers: Targeted sodium channel modulation
- Gene therapy: Viral vector delivery of neurotrophic factors
- Stem cell therapy: DRG neuron replacement
- Epidermal growth factor receptor (EGFR) inhibitors: Neuroprotective effects
- Identification of predictive genetic biomarkers
- Development of validated animal models
- Elucidation of sex differences in CIPN susceptibility
- Long-term natural history studies
The study of Peripheral Sensory Neurons In Chemotherapy Induced Neuropathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ferdousi M et al., Chemotherapy-induced peripheral neuropathy (2020)
- Staff NP et al., Taxane-induced peripheral neuropathy (2019)
- Schloss JM et al., Platinum-induced peripheral neuropathy (2020)
- Matsumoto M et al., Bortezomib-induced neuropathy (2019)
- Dorsey SG et al., CIPN mechanisms and biomarkers (2019)
- Smith EML et al., Duloxetine for CIPN (2019)
- Zajaczkowska R et al., Animal models of CIPN (2019)
- Colvin LA, Chemotherapy-induced neuropathy (2019)